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ABSTRACT
Fecal microbiota transplant (FMT) is a highly-effective therapy for recurrent Clostridioides difficile 
infection (rCDI), and shows promise for certain non-CDI indications. However, at present, its 
mechanisms of efficacy have remained poorly understood. Recent studies by our laboratory have 
noted the particular key importance of restoration of gut microbe-metabolite interactions in the 
ability of FMT to treat rCDI, including the impact of FMT upon short chain fatty acid (SCFAs) and bile 
acid metabolism. This includes a significant impact of these metabolites upon the life cycle of 
C. difficile directly, along with potential postulated additional benefits, including effects upon host 
immune response. In this Addendum, we first present an overview of these recent advancements in 
this field, and then describe additional novel data from our laboratory on the impact of FMT for rCDI 
upon several gut microbial-derived metabolites which had not previously been implicated as being 
of relevance.
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1. Introduction
Fecal microbiota transplant (FMT) is widely- 
recognized as a highly-efficacious treatment for 
recurrent/refractory Clostridioides difficile infec-
tion (rCDI) that has not responded to conven-
tional pharmacological therapy, such as 
fidaxomicin or vancomycin.1,2 There is also grow-
ing interest in the potential application of FMT 
for a range of non-CDI indications.3 However, 
there are certain clear drawbacks related to the 
use of FMT in its present form, including the 
complex regulation associated with its use, the 
potential need for invasive administration (i.e. 
endoscopy – although capsulized FMT is 
increasingly available), and the risk of transmis-
sion of infection from donor to recipient. The 
latter point is particularly salient, given a recent 
report of multi-drug resistant E. coli being trans-
mitted via FMT (to an immunosuppressed patient 
without rCDI) with a resultant patient death.4 
Furthermore, there are currently no established 
biological means for matching stool donor with 
recipient, despite certain proposals.5 As such, 
deconvoluting the mechanisms of efficacy of 
FMT – and exploiting this knowledge to develop 
novel targeted microbiome therapeutics, or to 
better match donor and recipient – is a major 
clinical priority.
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FMT for rCDI rapidly restores a gut microbiota, 
that has been hugely disrupted by recurrent antibio-
tic therapy, back toward pre-morbid composition 
and diversity, resembling that of healthy donors.6,7 
Proof-of-concept studies have further inferred the 
central role of restoration of gut bacteria specifically 
in the efficacy of FMT, demonstrating that either 
a healthy donor-derived defined community of com-
mensal bacteria8 or fractionated spores from etha-
nol-shocked donor stool9 may have comparable 
efficacy to conventional FMT in treating rCDI. 
However, a more recent pilot study demonstrated 
that sterile filtered donor stool (filtered through 
a 0.2 μm filter, small than the size of a bacterium) 
also effectively caused sustained remission from 
rCDI.10 This study raised the intriguing possibility 
that soluble factors – rather than intact bacteria 
per se – were key mediators for the efficacy of FMT.
Among such possible factors, non-bacterial gut 
microbiota components have been one area of focus. 
Several studies have described that the stool donor 
virome or mycobiome is associated with the efficacy 
of FMT for rCDI, and that these undergo rapid 
changes in the stool of rCDI patients treated success-
fully with FMT.11–14 However, the significance of 
these changes as a potential mechanism of efficacy 
of FMT remains unclear. For example, given the 
narrow range that bacteriophages possess, any anti- 
C. difficile lytic phages in the gut virome post-FMT 
would have had to have originated from C. difficile in 
the donor virome; given that C. difficile carriage is 
a near universal exclusion criterion for acceptance as 
an FMT donor, this would be very unlikely in practice. 
Similarly, given the established relationship between 
antimicrobial treatment and Candida overgrowth 
within the gut, any changes in gut mycobiome profiles 
post-FMT might only represent proxies of gut bacter-
ial alterations. Consequently, the specific contribution 
of bacteriophages and fungi to the efficacy of FMT 
remains undefined.
A further key area of interest has been whether 
a potential mechanism of FMT may be through the 
restoration of microbial metabolites, or of co- 
metabolites derived from interaction between the 
gut microbiota and host. This hypothesis has been 
the focus of much recent research from our labora-
tory. In the coming sections, we first summarize 
our recently-published work in this area, before 
introducing additional novel data.
2. Impact of FMT for rCDI upon gut microbial 
metabolites: recently-discovered areas
2.1. Bile acid metabolism
Different bile acids have varied effects upon the 
ability of C. difficile to undergo germination or 
vegetative growth in vitro. Specifically, the conju-
gated primary bile taurocholic acid (TCA) pro-
motes spore germination of C. difficile (with 
glycine functioning as pro-germinant);15,16 in con-
trast, secondary bile acids (including deoxycholic 
acid (DCA)) inhibit the vegetative growth and 
toxin activity of the bacterium.15,17 In mammals, 
conversion from primary to secondary bile acids 
occurs within the distal gut, undertaken by several 
enzymes produced by the gut microbiota, but not 
by mammals. The two principle enzymatic pro-
cesses are a first step mediated by bile salt hydrolase 
(BSH; which hydrolyzes the glycine or taurine 
group from conjugated bile acids, aka choloylgly-
cine hydrolase (EC 3.5.1.24)) and a second step by 
7-α-dehydroxylase (which converts unconjugated 
primary bile acids into secondary bile acids).18,19 
Recent studies demonstrated that the activity of 
bile-metabolizing enzymes (7-α-dehydroxylase in 
particular) is partly protective against CDI in 
rodents.20,21 Therefore, one hypothesis has been as 
to whether patients with rCDI – with antibiotic- 
mediated destruction of their gut microbiota – are 
deficient in gut microbiota members which pro-
duce bile-metabolizing enzymes, with the conse-
quent enrichment in TCA (promoting C. difficile 
germination) and loss of DCA (facilitating vegeta-
tive growth) perpetuating active disease. By exten-
sion, FMT may restore bacteria that produce these 
enzymes, and reverse the abnormal bile acid milieu 
of the distal gut.
Supporting this hypothesis, the stool bile acid 
milieu is enriched in TCA in human patients with 
rCDI, whilst secondary bile acids predominate in 
post-FMT stool.22–25 Similarly, healthy donor stool 
contains little TCA, but relatively high levels of 
secondary bile acids.22–24 Further recent work 
from our laboratories explored the dynamics of 
microbial bile acid-metabolizing enzymes in 
patients with rCDI, and the impact of FMT upon 
this. Predicted bsh gene abundance was signifi-
cantly reduced in patients with rCDI, compared to 
patients with a primary episode of CDI, and/or 
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healthy controls.24 Furthermore, the stool micro-
biota from patients pre-FMT had a greatly reduced 
relative abundance of a broad range of BSH- 
producing bacteria compared to the stool of 
patients treated successfully with FMT and/or 
healthy donors.23 Successful FMT for rCDI rapidly 
and sustainably restored stool bsh gene copy num-
ber and BSH functional activity from the almost 
negligible levels found pre-FMT up to comparably 
high levels to that found in healthy donors.23 
Finally, stool C. difficile counts were ~70% reduced 
in an rCDI mouse model after administration of 
E. coli expressing highly-active BSH relative to mice 
administered BSH-negative E. coli.23 Collectively, 
these data are strongly supportive that FMT- 
mediated restoration of gut microbial bile acid 
metabolism – and particularly BSH functionality – 
is a key mechanism underlying FMT’s efficacy in 
rCDI. An additional recent relevant finding has 
been that gut bacteria expressing 7-α- 
dehydroxylase are also able to produce tryptophan- 
derived antibiotics, which themselves inhibit the 
cell division of C. difficile.26
In addition to the direct action of bile acids upon 
C. difficile, recent findings hint at complementary 
mechanisms by which gut microbiota-bile acid inter-
actions contribute to protection from CDI. For exam-
ple, successful FMT for rCDI was also found to be 
associated with increased circulating fibroblast growth 
factor (FGF)-19, consistent with the upregulation of 
the farnesoid X receptor (FXR)-FGF pathway.27 In 
line with this, pre-treatment with the tertiary bile 
acid ursodeoxycholic acid (UDCA) in a CDI mouse 
model was associated with increased FXR-FGF signal-
ing-related transcripts and attenuated 
inflammation.28 Furthermore, upregulated FXR after 
FMT for rCDI may contribute to the resolution of the 
colitis induced by C. difficile, since FXR agonist 
administration in a rodent colitis model was asso-
ciated with reduced colonic inflammation and 
a more intact intestinal barrier.29 Ileal FXR activation 
also causes reduced hepatic bile acid synthesis by 
negative feedback; this may result in reduced TCA 
secretion into the gut, further reducing germination 
of C. difficile. Additionally, microbially-mediated pro-
duction of certain secondary bile acids has been 
demonstrated to promote the generation of peripheral 
regulatory T cells,30 linking these metabolites with 
colonic immunity.
2.2. Short chain fatty acid metabolism
One further group of metabolites well-studied in 
this field are the short chain fatty acids (SCFAs). 
The major source of these is bacterial fermentation 
of partially and non-digestible carbohydrates (pri-
marily dietary), although certain amino acids may 
also be a source.31 In rodent studies, while antibio-
tics reduced SCFA levels in stool, higher SCFA 
levels were found to be associated with protection 
from C. difficile growth, suggesting an interplay 
between antibiotics, SCFAs, and rCDI risk.17
Human studies have demonstrated that levels of 
a range of SCFAs within stool (including acetate, 
propionate and butyrate) are very low in rCDI, but 
restored to levels comparable to healthy donors 
after successful FMT.25 However, given the close 
link between antibiotic use, dietary intake and 
SCFA production, it is difficult to ascertain from 
human observational studies alone whether the 
post-FMT increase in stool SCFAs reflects changes 
in dietary intake and/or recovery after antibiotic 
discontinuation post-resolution of CDI, or whether 
this is driven by specific FMT-related gut micro-
biota changes.
As such, our laboratory investigated this using an 
artificial gut (“chemostat”) model of CDI, whereby 
the confounding factor of variable dietary intake 
was removed.32 In these experiments, recovery of 
the levels of certain SCFAs (including butyrate) was 
observed after cessation of antibiotics and even 
prior to FMT, consistent with spontaneous gut 
microbiota recovery. However, levels of valerate 
(the five carbon SCFA) only recovered to baseline 
levels after the administration of FMT, and not 
after antibiotic cessation alone. Valerate caused 
a dose-dependent inhibition of the vegetative 
growth of several C. difficile ribotypes, but no 
adverse growth effects upon several different com-
mon gut commensal bacteria. In a CDI mouse 
model, oral administration of valerate (in the 
form of glycerol trivalerate) resulted in a ~ 95% 
reduction in C. difficile stool counts compared to 
control-treated mice.32 Additionally, successful 
FMT for rCDI in humans was associated with 
rapid, sustained restoration of stool valerate to 
similar levels as found in stool donors.32
Restoration of SCFAs by FMT may benefit 
patients recovering from CDI by mechanisms 
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beyond inhibiting the growth of C. difficile, includ-
ing a possible role in the resolution of colitis and gut 
barrier function. For instance, in a mouse model of 
CDI, butyrate was demonstrated to improve intest-
inal barrier function and reduce intestinal inflam-
mation via a mechanism involving activation of the 
transcription factor HIF-1.33 Furthermore, SCFAs 
regulate the size and function of the colonic regula-
tory T cell population in mice, which has been 
directly demonstrated to be a protective mechanism 
against colitis.34 SCFAs (including valerate) are also 
recognized to inhibit histone deacetylases (HDACs), 
with the resultant change in transcription of a range 
of genes having a net anti-inflammatory effect on 
the host immune phenotype.35,36 Of particular rele-
vance, exogenous valerate has already been shown 
to ameliorate chemically-induced colitis in a rodent 
model via HDAC inhibition.37
3. Impact of FMT for rCDI upon gut microbial 
metabolites: novel areas
To investigate further metabolic pathways that FMT 
for rCDI may impact upon, we performed proton 
nuclear magnetic resonance spectroscopy (1H- 
NMR) on stool (fecal water) and urine from rCDI 
patients participating in a clinical trial comparing 
capsule to colonoscopic delivery of FMT, with 
samples collected prior to FMT, and at weeks 1, 4, 
and 12 post-FMT.38 Samples from 18 patients and 3 
donors were analyzed; further details on methodol-
ogy are provided in the Supplementary 
Material.1H-NMR is an ‘information-rich’ analytical 
technique used in metabonomics and popular for its 
capability to simultaneously detect many biochem-
ical entities (host and microbial) from complex bio-
fluids in a nondestructive manner.39
Global metabolic profiling of fecal water changed 
notably after FMT, with pre-FMT samples cluster-
ing apart from post-FMT and donor samples across 
the first principal component in the principal com-
ponents analysis (PCA) scores plot (Figure 1). This 
indicates that patients acquired a stool metabolic 
profile more similar to donors already in the first 
week post-FMT, and this was maintained for 
12 weeks. We did not observe any strong effect of 
the FMT mode on the metabolic profile 
(Supplementary Figure 1a). To assess the propor-
tion of features changing after FMT, we used mixed 
effects models40 with time as categorical variable 
and using our first time point (pre-FMT) as refer-
ence category. Specifically, we tested the time effect 
as a likelihood ratio test among two models – with 
or without time as the predictor – fitted to each 
NMR feature (binned spectra intensities): NMR 
feature ~ time + FMT mode + (1|Donor) + (1| 
a b
Figure 1. Metabolic profile differences in donors and recipients before and after FMT. Principal component analysis (PCA) scores plots 
of1H-NMR spectra from fecal water (a) and urine (b) samples from donors (n = 3) and recipients collected at different timepoints (for 
stool recipient samples: n = 18 for timepoints 0 (pre-FMT), 1, 4 and n = 16 for timepoint 12; for urine: n = 15 for timepoint 0, n = 12 for 
timepoint 1, n = 13 for timepoints 4 and 12).
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Recipient). A total of 15,162 out of 21,252 (≈71%) 
features from fecal water changed with time, which 
agrees with the clear clustering already observed in 
the PCA (Figure 1(a)). Using statistical total corre-
lation spectroscopy (STOCSY),41 2D J-resolved 
(JRES)1H-NMR spectra and NMR peak databases, 
we annotated different metabolites and calculated 
the area under the curve (AUC) of a representative 
peak for each, using spectra normalized by prob-
abilistic quotient normalization (PQN).42
In stool, the SCFAs acetate, butyrate and propio-
nate increased 4.96, 2.46 and 3.46 median fold at 
12 weeks post-FMT, respectively (Figure 2), con-
sistent with previous findings, as described above. 
Further analysis and interpretation regarding the 
effect of FMT upon SCFAs (as well as upon bile 
acids) is provided within the Supplementary 
Material. Interestingly, we also detected a 1.7-fold 
increase in the microbial metabolite trimethyla-
mine (TMA; produced by gut bacteria from dietary 
choline and L-carnitine), a 1.95-fold increase in the 
pyrimidine uracil, and a 0.55-fold decrease in the 
carboxylic acid malonate (Figure 2). To our knowl-
edge, this is the first time an increase in TMA is 
reported following FMT intervention in patients 
with rCDI. Similarly, an increase in uracil has not 
been reported previously, although a decrease in 
this metabolite has been observed in feces from 
mice treated with vancomycin;43 as such, the 
observed uracil increase could be to at least partly 
a proxy of gut ecology recovery after cessation of 
vancomycin, rather than an effect of FMT per se. 
The decrease in malonate after FMT has also not 
been described before. The capacity to metabolize 
malonate by the gut microbiota and its impact on 
host metabolism has not previously been character-
ized in detail, but appears to be negatively- 
correlated with acetate across different experimen-
tal landscapes,44,45 and could be associated with an 
increase in gut bacteria using this metabolite as 
energy source.
In urine, PCA scores did not show clear clus-
ters among different groups or FMT modes 
(Figure 1(b) and Supplementary Figure 1b), but 
3,099 out of 27,271 features (≈11%) changed with 
time. Particularly, we found a 3.46-fold increase 
in the microbial-host co-metabolite hippurate 
(produced by conjugation of the microbial com-
pound benzoate with glycine in the liver), a 1.85- 
fold increase in the co-metabolite trimethyla-
mine-N-oxide (TMAO; resulting from TMA oxi-
dation in the liver), and a 2.8-fold increase in 
4-cresol sulfate (4-CS; the hepatic sulfonation of 
microbial 4-cresol). Finally, we also found a 1.34- 
fold increase in phenylacetylglutamine (PAG) 
(although this was not significant at the 5% sig-
nificance level), while no differences were found 
in creatinine (Figure 3). As with fecal uracil, the 
observed increases in hippurate and PAG could 
reflect recovery of gut microbial ecology after 
vancomycin cessation, as those two metabolites 
were also reduced in urine from mice treated 
with vancomycin.43
The increase in urinary TMAO correlates with 
the observed increase in fecal TMA (Figure 2), 
suggesting a higher availability of TMA for oxida-
tion in the liver. This could also be a consequence 
of microbial restoration after FMT, as the previous 
study shows an increase in urine TMAO in control 
mice as compared to those treated with antibiotic. 
TMA and TMAO synthesis is markedly altered 
after antibiotic treatment in humans, with gut 
microbial production of TMA from L-carnitine 
Figure 2. Metabolite changes in fecal water. Area under curve 
(AUC) of metabolite representative peaks at 0 (pre-FMT) and 
12 weeks post-FMT (top; n = 18 for timepoint 0 and n = 16 for 
timepoint 12), and across all measured time points (bottom; 
n = 18 for timepoints 0, 1, 4 and n = 16 for timepoint 12). 
P-values were calculated using paired Wilcoxon signed rank test.
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appearing to involve multiple commensal bacteria 
(only partially identified) rather than a single com-
munity member.46 However, given the association 
of TMAO with atherosclerosis,47 long-term effects 
of FMT on TMA and TMAO levels in recipient 
patients deserves further investigation, as well as 
potentially the need to triage donors according to 
their TMA or TMAO levels; this is particularly of 
relevance given the interest of the potential role of 
FMT in treating obesity/metabolic syndrome 
(MetS). Given that a vegan diet is associated with 
reduced capacity to synthesize TMAO on the so- 
called ‘carnitine challenge’47 Smits and colleagues 
performed a pilot study where 20 male MetS 
patients were randomized to either receive lean 
vegan donor FMT or autologous FMT.48 
Interestingly, while certain gut microbiota changes 
were seen in the vegan donor FMT recipients, there 
was neither an improvement of arterial wall inflam-
mation, nor a change in TMA/TMAO metabolism, 
by two weeks post-FMT.48 The value of vegan FMT 
donors for MetS treatment – together with patient 
diet and exercise patterns post-FMT – needs to be 
further evaluated in larger cohorts, and its impact 
on TMA/TMAO metabolism and associated gut 
microbes further explored using ‘confounder- 
reduced’ batch cultures and/or mouse models. 
Additionally, a clinically-applicable means of asses-
sing the ability of the gut microbiota to produce 
TMAO – through the oral carnitine challenge test49 
– may be a useful test for screening of donors in the 
future.
The increase in 4-CS post-FMT is somewhat less 
expected, given that 4-cresol is produced by 
C. difficile.50 4-CS has been associated with inflam-
mation and a range of diseases, including kidney 
failure, autism, and colorectal cancer.51,52 The lack 
of change in creatinine levels after FMT (Figure 3) 
indicates that kidney function does not appear to be 
affected by the intervention. As such, one possible 
explanation may be that FMT disrupts the life cycle 
of C. difficile without necessarily causing its clear-
ance from the gut. Another explanation for the 
increase in urinary 4-CS is that it may reflect 
increased bacterial production of 4-cresol after 
FMT, restored by any of the number of non- 
C. difficile gut bacteria which also produce this 
metabolite,53 with the possible concomitant shift 
toward increased consumption of proteins as the 
patient symptoms improve. This would provide the 
gut microbiota higher amounts of amino acid tyr-
osine, the 4-cresol substrate. However, detailed 
dietary data in our study was not available, which 
is a limitation of this study when interpreting 
changes in TMAO and 4-cresol. As with TMAO, 
the long-term impact of FMT on 4-CS levels, and 
possible causes for its increase other than rCDI – or 
whether it relates to a higher risk of recurrence – 
remains to be assessed.
4. Conclusions
Our past work and the novel results presented in 
this Addendum suggest a strong impact of FMT 
on the metabolic profile of recipients soon after 
intervention. Mechanistic insights using mouse 
models, chemostats or human samples on the 
role of these metabolites during rCDI could 
give us further insight into the pathogenesis of 
rCDI, biomarkers of FMT outcomes, and – of 
greatest clinical relevance – the potential to 
replace FMT with a more refined microbial ther-
apeutic, e.g. a ‘cocktail’ of purified BSH and 
glycerol trivalerate. Furthermore, consequences 
Figure 3. Metabolite changes in urine. AUC of metabolite repre-
sentative peaks at 0 (pre-FMT) and 12 weeks post-FMT (top; 
n = 15 for timepoint 0 and n = 13 for timepoint 12), and across 
all measured time points (bottom; n = 15 for timepoint 0, n = 12 
for timepoint 1, n = 13 for timepoints 4 and 12). P-values were 
calculated using paired Wilcoxon signed rank test.
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of such metabolic shifts, especially at later fol-
low-up time points and controlling for dietary 
factors, need further investigation, and may be 
of particular significance as FMT usage extends 
beyond CDI and into other diseases.
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